Int. J. Radiat. Oncol. Biol. Phys. 2019 Nov 29
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.
ABSTRACT
BACKGROUND
Phase 2 cooperative group meningioma trial assessing the safety and efficacy of risk-adaptive management strategies. This is the initial analysis of the high-risk cohort.
METHODS AND MATERIALS
High-risk patients were those with a new or recurrent World Health Organization (WHO) grade III meningioma of any resection extent, recurrent WHO grade II of any resection extent, or new WHO grade II after subtotal resection. Patients received intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions). Three-year progression-free survival (PFS) was the primary endpoint. Adverse events (AEs) were scored per NCI Common Terminology Criteria for Adverse Events version 3.
RESULTS
Of 57 enrolled patients, 53 received protocol treatment. Median follow-up was 4.0 years (4.8 years for living patients). Two patients withdrew without progression before year 3; for the remaining 51 patients, 3-year PFS was 58.8%. Among all 53 protocol-treated patients, 3-year PFS was 59.2%. Three-year local control was 68.9%, and overall survival was 78.6%. Of 51 patients, 1 patient (1.9%) experienced a late grade-5 necrosis-related AE. All other acute (23 of 53 patients) and late (21 of 51 patients) AEs were grades 1 to 3.
CONCLUSIONS
Patients with high-risk meningioma treated with IMRT (60 Gy/30) experienced 3-year PFS of 58.8%. Combined acute and late AEs were limited to grades 1 to 3, except for a single necrosis-related grade 5 event. These results support postoperative IMRT for high-risk meningioma and invite ongoing investigations to improve outcomes further.
Related Questions
What dose/volumes would you recommend for a previously radiated tumor not amenable to surgical resection?
New answer by Radiation Oncologist at University of Louisville School of Medicine (May 14, 2020)
In general, the prognosis of recurrent anaplastic meningioma after previous surgery and radiation is poor. I usually try to persuade my neuro-oncology colleague to use bevaciz...
Several articles report results with 0.5 -1 cm margins, and have suggested that with improved imaging and treatment planning, smaller margins such as ...
New comment by Radiation Oncologist at Mallory Radiotherapy, PLLC ( March 23, 2023)
How would you treat a patient who received 5 Gy x 5 with Cyberknife 8 years prior and subsequently progressed and underwent GTR with path showing grade 2?
What dose/fractionation do you prefer?
New answer by Radiation Oncologist at Columbia University Irving Medical Center (September 16, 2020)
Metastatic meningioma outside the CNS is rare, and its incidence has been estimated to be 0.1% with the lung being the most common site for distant metastases (Surov et al., P...
When do you consider observation?
New comment by Radiation Oncologist at The Oregon Clinic-Radiation Oncology West ( February 1, 2023)
I agree, offer postop fractionated radiotherapy for de novo completely resected atypical meningioma while we await the phase III trial results.
Would your recommendation for ...
Is there a dose response between 4500 and 5040 cGy?
New comment by Radiation Oncologist at GammaWest Cancer Services ( October 30, 2024)
Dr. @Riegert notes varied fractionation options. From an alpha-beta perspective, and likely even with regard to tumor control, this is likely so. However, we know less about s...
Is there diminished radiotherapy efficacy in tumor control after certain timeframe has passed for malignant meningiomas with no signs of recurrent dis...
New answer by Radiation Oncologist at Turville Bay MRI & Radiation Oncology Center (August 22, 2023)
Adjuvant radiation for grade 3 meningioma is based on prior observational studies that generally reflect recurrence rates approaching 90% for grade III disease, and the insuff...